ERBB2 and neoplasm: In addition, trastuzumab triggers antibody-dependent cellular cytotoxicity (ADCC) [95], marking HER2-overexpressing tumor cells for immune-mediated destruction by recruiting natural killer (NK) cells and other immune effectors.